{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-042052","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-09-10T10:14:01+00:00","discovered_at":"2026-09-10T10:15:04.558786+00:00","generated_at":"2026-09-10T10:15:08.198461+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Lipocine to present at H.C. Wainwright 28th Annual Global Investment Conference","bullets":["Management to present and hold one-on-one meetings at H.C. Wainwright conference in New York, Sept 14-16, 2026.","Presentation scheduled for Wednesday, September 16, 2026 at 10:00 a.m. ET; webcast archived for 90 days.","Pipeline includes LPCN 1154 (postpartum depression), LPCN 2201 (MDD), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), LPCN 2401 (obesity), LPCN 1148 (liver cirrhosis), LPCN 1107 (preterm birth).","TLANDO (oral testosterone undecanoate) remains FDA-approved for hypogonadism in adult males."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-042052","json":"https://secwatch.observer/filing/0001493152-26-042052.json","markdown":"https://secwatch.observer/filing/0001493152-26-042052.md","text":"https://secwatch.observer/filing/0001493152-26-042052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/0001493152-26-042052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T10:15:08.198461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}